TD Cowen Sticks to Their Buy Rating for Cannara Biotech (LOVFF)
I'm LongbridgeAI, I can summarize articles.TD Cowen analyst Derek Lessard has reaffirmed a Buy rating for Cannara Biotech (LOVFF), setting a price target of C$3.25, while the stock closed at C$1.82. The analyst consensus for Cannara is Strong Buy, with a target of C$3.09, indicating a potential upside of 69.76%. Atrium Research also maintains a Buy rating with a C$3.00 target. Lessard has a -1.5% average return and a 47.37% success rate on his stock recommendations.
In a report released yesterday, Derek Lessard from TD Cowen maintained a Buy rating on Cannara Biotech, with a price target of C$3.25. The company’s shares closed yesterday at C$1.82.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Lessard covers the Consumer Cyclical sector, focusing on stocks such as MTY Food Group, Boyd Group Services, and Dorel Class B. According to TipRanks, Lessard has an average return of -1.5% and a 47.37% success rate on recommended stocks.
Cannara Biotech has an analyst consensus of Strong Buy, with a price target consensus of C$3.09, implying a 69.76% upside from current levels. In a report released on April 14, Atrium Research also maintained a Buy rating on the stock with a C$3.00 price target.